A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients With Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06343636

Enrollment

115

Registered

2024-04-02

Start date

2023-09-22

Completion date

2025-01-10

Last updated

2025-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, Healthy

Brief summary

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927.

Interventions

DRUGVG-3927

Dose Escalation

DRUGPlacebo

Dose Escalation

Study design

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* The participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation * The participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent

Exclusion criteria

* The participant has any concurrent disease or condition that, in the opinion of the principal investigator, would make the participant unsuitable for participation in the clinical study

Design outcomes

Primary

Measure	Time frame	Description
Adverse Events	28 days post last dose	To evaluate the safety and tolerability of VG-3927

Countries

Australia, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026